# Repligen Corporation  Share Price Target ‘$199.98’, now 3.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-share-price-target-199.98-now-3.8-upside-potential/4121145131
- Published: 2024-02-29T13:37:09+00:00
- Author: Charlotte Edwards

**Repligen Corporation** with ticker code (RGEN) now have 11 confirmed analysts 
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $225.00 and $160.00 calculating
the mean target share price we have $199.98. (at the time of writing). Given that
the stocks previous close was at $192.71 this would imply there is now a potential
upside of 3.8%. The day 50 moving average is $187.58 and the 200 day moving average
is $165.33. The total market capitalization for the company now stands at 10.93B.
The stock price is currently at: $195.94 USD

 The potential market cap would be $11,340,040,763 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 264.78, revenue per share of $11.46 and a 1.31% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on: